Emma Dean

5.5k citations
132 papers · 2.7k · 1 hit paper · h-index 29

Impact in

  • Oncology top 2%
    • PARP inhibition in cancer therapy
    • Cancer-related Molecular Pathways
    • Cancer, Hypoxia, and Metabolism

Papers in

    • PARP inhibition in cancer therapy 40
    • Lung Cancer Research Studies 12
    • Colorectal Cancer Treatments and Studies 10
    • DNA Repair Mechanisms 33
    • Cell death mechanisms and regulation 16
    • Cancer therapeutics and mechanisms 16

Emma Dean

127 papers receiving 2.6k citations

Emma Dean's Hit Papers

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors 2021 · 192 citations
1920+1+3Years since publication50100150

Peers

Emma Dean
Comparison fields: 5 of 101
  • Oncology 1.4k
  • Cancer Research 436
  • Molecular Biology 1.8k
  • Reproductive Medicine 175
  • Pathology and Forensic Medicine 222
Replace T. Khanh with:
T. Khanh United States
Hitoshi Zembutsu Japan
Antonella Papa United States
Frank Wu United States
Thomas Bogenrieder Germany
L. Rhoda Molife United Kingdom
Giulio Francia United States
Ben Markman Australia
Patrick G. Pilié United States
Ingrid Hedenfalk Sweden
Emma Dean relative to T. Khanh United States T. Khanh's profile →
Citations per field
00.5×1.5×2.1×
T. Khanh · 1×
Citations per year

Countries citing papers authored by Emma Dean

Since Specialization
Citations

This map shows the geographic impact of Emma Dean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Dean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Dean more than expected).

Fields of papers citing papers by Emma Dean

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Dean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Dean. The network helps show where Emma Dean may publish in the future.

Co-authors

The 25 scholars most cited alongside Emma Dean, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Emma Dean Line = papers co-authored together Emma Dean links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 132 papers — load more, or switch the sort, to bring in the rest.

#Work
1
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
Hit paper breakdown →
2021192
2 2020126
3 2008109
4 2016104
5 2012103
6 2015102
7 202188
8 201883
9 202181
10 202171
11 201966
12 200966
13 202161
14 200761
15 202259
16 202156
17 202340
18 201540
19 200738
20 201638

About Emma Dean

Emma Dean is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 132 papers that have together received 2.7k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (40 papers), DNA Repair Mechanisms (33 papers), Lung Cancer Treatments and Mutations (19 papers), Cell death mechanisms and regulation (16 papers), Cancer therapeutics and mechanisms (16 papers), Lung Cancer Research Studies (12 papers), Colorectal Cancer Treatments and Studies (10 papers) and Ovarian cancer diagnosis and treatment (10 papers). The work is most often cited by research in Oncology (1.4k citations), Cancer Research (436 citations), Molecular Biology (1.8k citations), Reproductive Medicine (175 citations) and Pathology and Forensic Medicine (222 citations). Emma Dean has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Malcolm Ranson, Caroline Dive, Alastair Greystoke, Mark R. Middleton, Fiona Blackhall, Simon A. Smith, Helen Swaisland, Ruth Plummer, Peter G. Mortimer and Geoffrey I. Shapiro. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, British Journal of Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact